Interesting you bring this up Speccys good call. Shows just how unbelievably undervalued we are. We are much later stage ramping up more clinical sites. And, that pipeline is primarily going after haematological malignancies (blood cancers) with most IND's expected 2024. The share price is irrelevant now IMO to realise the true potential and windfall of CHM you just gotta hang onto your shares. You wont see me selling at $1 ($400m MC). 1/3 of the money in the ASX is from O/S investment, it's only a matter of time before CHM gets noticed for it's world class pipeline and management. Especially as we see more data soon and more left field combination studies and partnerships.
Another one, if you look at Celularity Nasdaq (CELU) which was also $1.8b in May this year (and only had good news during it's drop). They are only marginally infront of CHM in their clinical stages. Ok, they have a placental harvesting business for a bit of revenue but for CHM to be valued 45x less than their MC ($42m) is crazy.
Nasdaq Biotech's were up 2.18% overnight and IBB ishare biotech ETF was up 2.20% they are starting to see some money again.
CHM Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)